Liver metastases of neuroendocrine tumors are usually slow-growing, and cyt
oreductive hepatectomy can help reduce the effects of endocrinopathies and
increase life expectancy and symptom-free survival. However, it has yet to
be fully investigated how hepatectomy for metastatic neuroendocrine tumors
can be performed safely. Here we report the results of 13 patients with neu
roendocrine liver metastases operated on in our institution and those of a
French multicentric study that included 131 patients. Preoperative patient
selection and appropriate surgical technique, sometimes combined with preop
erative portal embolization and local tumor destruction (radiofrequency and
cryotherapy), may increase the resectability and the safety of the procedu
re. The mortality rate after hepatectomy was 0% (2.3% in the French study);
the 3- and 6-year survival rates were 91% and 68%, respectively, in our in
stitution (the mean survival time was 66 months in the French multicentric
survey). Significant prolonged survival with complete palliation of symptom
s can be obtained after liver metastases resection with low mortality.